Trial
NCT04441138
Chemoradiation Followed by Durvalumab in Poor Risk and/or Elderly Patients With Stage III NSCLC
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Rush University Medical Center
Collaborators
AstraZeneca
Condition
Stage III Non-small-cell Lung Cancer
Intervention
Durvalumab
Why stopped
Institutional constraints due to research staffing and diminished data safety monitoring infrastructure
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-05-28